Medsenic Being Granted US Patent for Arscimed for RRMS

Medsenic Being Granted US Patent for Arscimed for RRMS

308789

Medsenic Being Granted US Patent for Arscimed for RRMS

The U.S. Patent and Trademark Office will grant Medsenic a patent covering the use of Arscimed, its investigational formulation of arsenic trioxide, for the treatment of relapsing-remitting multiple sclerosis (RRMS). Once issued, the patent will protect Arscimed’s use for this indication until 2037. This will add to the already robust family of U.S. patents protecting Arscimed for additional indications. “This patent represents a further recognition in the strategic US market of the very original properties of…

You must be logged in to read/download the full post.